Anixa Biosciences CEO Amit Kumar buys $21,760 in stock

Anixa Biosciences CEO Amit Kumar increased his stake in the company by purchasing 8,000 shares on October 22, 2026. The transaction, valued at $21,760, occurred at a stock price of $2.72 per share. Kumar now owns a total of 680,000 shares. Despite the stock's significant decline of 31% over the past year, analysts suggest the shares are overvalued, with price targets ranging from $6 to $14.

Anixa Biosciences maintains a robust balance sheet with more cash than debt and a current ratio of 8.54, although profitability is not expected for this year. Recent developments include a positive response in a Phase 1 trial for a CAR-T cell therapy in recurrent ovarian cancer, and a patent granted for their breast cancer vaccine technology in Australia.